Multicenter Analysis of Neoadjuvant Docetaxel, Carboplatin, and Trastuzumab (TCH) in Patients With HER2-Positive Breast Cancer

This retrospective analysis reviewed all the incident stage I-III HER2-positive breast cancer patients who received neoadjuvant TCH in three institutions. Overall, TCH was well tolerated, with low rates of grade 3-4 adverse events, and neither late toxicities nor cardiac dysfunctions were reported.

 Breast Cancer Res Treat

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.